Prevents Pneumocystis jirovecii pneumonia (PCP). ANDA 212918, held by Bionpharma. Atovaquone.
As of Nov 20, 2026, ANDA 212918 (Atovaquone), held by Bionpharma, was first approved by FDA on Mar 30, 2021, with 1 approved supplement and 0 published complete response letters.
1 INDICATIONS AND USAGE ------------------- INDICATIONS AND USAGE -------------------- Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. Limitations of Use: Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] > 45 mm Hg) with atovaquone has not been studied. The efficacy of atovaquone in subjects who are failing therapy with TMP-SMX has also not been studied. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML · suspension;oral | Atovaquone | Rx |
| Sep 24, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 30, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters